Siyuan Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Siyuan Ding has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Keran Li
Department of Ophthalmology, The Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China
2 shared publications - Ziyi Chen
Department of Ophthalmology, Eye Hospital of Nanjing Medical University, Nanjing 210029, China
2 shared publications - Guangguang Wu
Department of Ophthalmology, Eye Hospital of Nanjing Medical University, Nanjing 210029, China
1 shared publication - Jiajun Li
Department of Ophthalmology, Eye Hospital of Nanjing Medical University, Nanjing 210029, China
1 shared publication - Jiayi Li
The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 211166, China
1 shared publication - Qin Jiang
The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6599
Clinical Interchangeability Boundaries of Pentacam AXL WAVE in Preoperative Biometry for Cataract Surgery: An Agreement Study with IOLMaster 700 and Pentacam
Background/Objectives: Accurate preoperative biometry is essential for refractive cataract surgery. Pentacam AXL WAVE is an emerging multimodal platform integrating ocular biometry, anterior segment imaging, and corneal assessment, yet its interchangeability with established devices remains unclear. This study aimed to evaluate the agreement and clinical interchangeability of Pentacam AXL WAVE with IOLMaster 700 and Pentacam. Methods: This retrospective cross-sectional study compared Pentacam AXL WAVE with IOLMaster 700 and Pentacam across 175 eyes of 105 cataract patients. Interdevice agreement was evaluated using intraclass correlation coefficients, concordance correlation coefficients, and Bland–Altman analysis with multiple outlier-handling strategies; generalized estimating equations were applied to identify clinical factors associated with interdevice differences. Results: Pentacam AXL WAVE demonstrated good agreement with IOLMaster 700 and Pentacam for axial length and anterior corneal curvature parameters, but showed weaker agreement for white-to-white diameter, total keratometry, total corneal astigmatic vectors, and several extended anterior segment parameters. Fewer clinical factors explained interdevice differences versus IOLMaster 700, whereas ocular surface or corneal abnormalities, refractive status, and cataract characteristics were associated with greater differences versus Pentacam. Conclusions: These findings indicate that Pentacam AXL WAVE has parameter-specific interchangeability boundaries and can meet some routine biometric needs; however, for eyes requiring high refractive precision or presenting with complex ocular conditions, interpretation should be based on the agreement characteristics of individual parameters.
- 26 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6599
Open AccessClinical Interchangeability Boundaries of Pentacam AXL WAVE in Preoperative Biometry for Cataract Surgery: An Agreement Study with IOLMaster 700 and Pentacam
Background/Objectives: Accurate preoperative biometry is essential for refractive cataract surgery. Pentacam AXL WAVE is an emerging multimodal platform integrating ocular biometry, anterior segment imaging, and corneal assessment, yet its interchangeability with established devices remains unclear. This study aimed to evaluate the agreement and clinical interchangeability of Pentacam AXL WAVE with IOLMaster 700 and Pentacam. Methods: This retrospective cross-sectional study compared Pentacam AXL WAVE with IOLMaster 700 and Pentacam across 175 eyes of 105 cataract patients. Interdevice agreement was evaluated using intraclass correlation coefficients, concordance correlation coefficients, and Bland–Altman analysis with multiple outlier-handling strategies; generalized estimating equations were applied to identify clinical factors associated with interdevice differences. Results: Pentacam AXL WAVE demonstrated good agreement with IOLMaster 700 and Pentacam for axial length and anterior corneal curvature parameters, but showed weaker agreement for white-to-white diameter, total keratometry, total corneal astigmatic vectors, and several extended anterior segment parameters. Fewer clinical factors explained interdevice differences versus IOLMaster 700, whereas ocular surface or corneal abnormalities, refractive status, and cataract characteristics were associated with greater differences versus Pentacam. Conclusions: These findings indicate that Pentacam AXL WAVE has parameter-specific interchangeability boundaries and can meet some routine biometric needs; however, for eyes requiring high refractive precision or presenting with complex ocular conditions, interpretation should be based on the agreement characteristics of individual parameters.
- Open Access
- 22 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (6) , 763
Calcium at the Helm: Mechanisms and Therapeutic Targets in the Retinal Neurovascular Unit
Retinal neurovascular unit (RNVU) dysfunction underlies major blinding and neurodegenerative conditions including glaucoma, diabetic retinopathy (DR), age-related macular degeneration (AMD), retinal ischemia–reperfusion (RIR) injury, and Alzheimer’s disease (AD)-associated retinopathy. Within the RNVU, calcium ions coordinate neurotransmission, glial activation, vascular tone, and blood–retinal barrier maintenance, and calcium dysregulation is emerging as a unifying pathogenic hub across these conditions. Although upstream triggers differ, including mechanical stress in glaucoma, hyperglycemia in DR, oxidative damage in AMD, ischemic energy failure in RIR, and amyloid-β–driven endoplasmic reticulum stress in AD, all converge on disruption of intracellular calcium homeostasis, producing shared downstream consequences including excitotoxic injury of retinal ganglion cells (RGCs), Müller cell reactive gliosis, and pericyte hypercontraction. Broad-spectrum calcium channel blockade has shown limited clinical success, underscoring the need for cell-type-specific and pathway-selective approaches. This review therefore catalogs key interventional nodes, including transient receptor potential (TRP) channel antagonists, T-type calcium channel inhibitors, calcium/calmodulin-dependent protein kinase II (CaMKII) suppressors, and mitochondrial permeability transition pore (mPTP) inhibitors, and discusses how precision targeting of these pathways may restore RNVU homeostasis and open a therapeutic window into central nervous system (CNS) degenerative disorders.
- 22 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (6) , 763
Open AccessCalcium at the Helm: Mechanisms and Therapeutic Targets in the Retinal Neurovascular Unit
Retinal neurovascular unit (RNVU) dysfunction underlies major blinding and neurodegenerative conditions including glaucoma, diabetic retinopathy (DR), age-related macular degeneration (AMD), retinal ischemia–reperfusion (RIR) injury, and Alzheimer’s disease (AD)-associated retinopathy. Within the RNVU, calcium ions coordinate neurotransmission, glial activation, vascular tone, and blood–retinal barrier maintenance, and calcium dysregulation is emerging as a unifying pathogenic hub across these conditions. Although upstream triggers differ, including mechanical stress in glaucoma, hyperglycemia in DR, oxidative damage in AMD, ischemic energy failure in RIR, and amyloid-β–driven endoplasmic reticulum stress in AD, all converge on disruption of intracellular calcium homeostasis, producing shared downstream consequences including excitotoxic injury of retinal ganglion cells (RGCs), Müller cell reactive gliosis, and pericyte hypercontraction. Broad-spectrum calcium channel blockade has shown limited clinical success, underscoring the need for cell-type-specific and pathway-selective approaches. This review therefore catalogs key interventional nodes, including transient receptor potential (TRP) channel antagonists, T-type calcium channel inhibitors, calcium/calmodulin-dependent protein kinase II (CaMKII) suppressors, and mitochondrial permeability transition pore (mPTP) inhibitors, and discusses how precision targeting of these pathways may restore RNVU homeostasis and open a therapeutic window into central nervous system (CNS) degenerative disorders.